BRIACELL THERAPEUTICS CORP. Finite-Lived Intangible Asset, Expected Amortization, Year One
BRIACELL THERAPEUTICS CORP. (BCTX) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $15.27 thousand as of 2025-07-31, per its 10-K filed 2025-10-16.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2025-10-16
- 2025-07-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $15.27K.
- 2024-07-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $15.27K.
- 2023-07-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $15.27K.
- 2022-07-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $15.27K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-07-31 | $15.27K 10-K · filed 2025-10-16 |
| 2024-07-31 | $15.27K 10-K · filed 2024-10-29 |
| 2023-07-31 | $15.27K 10-K · filed 2023-10-25 |
| 2022-07-31 | $15.27K 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |